Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in Metastatic Colorectal Cancer
CTR20160482Phase 3Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donafenib in metastatic colon cancer (mCRC), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Sep 2016; status: completed.
02
Drugs
donafenib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20160482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160482.